PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of intjangiolInternational Journal of Angiology HomepageInstructions for AuthorsSubscribeAboutEditorial BoardThieme
 
Int J Angiol. Mar 2012; 21(1): 53–58.
Prepublished online Feb 17, 2012. doi:  10.1055/s-0032-1302436
PMCID: PMC3444034
Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction
Refik Erdim, M.D., F.E.S.C.,1 Funda Helvacioglu, M.D.,2 Selcuk Gormez, M.D., F.E.S.C.,1 Kanber Ocal Karabay, M.D.,1 and Vedat Aytekin, M.D., F.E.S.C.1
1Department of Cardiology, Florence Nightingale Hospital, Istanbul, Turkey
2Department of Cardiology, Pendik State Hospital, Istanbul, Turkey
Address for correspondence and reprint requests Refik Erdim, M.D., F.E.S.C.Department of Cardiology, Florence Nightingale Hospital, Abide-i-Hurriyet Caddesi, No. 290, 80220, Istanbul, Turkey, ; errefik/at/hotmail.com
It has been shown that drug-eluting stents (DESs) significantly reduce restenosis rate when compared with bare-metal stents in a broad range of patients with coronary artery disease. However, current data are limited about the efficacy of different DESs in treatment of ST segment elevation myocardial infarction (STEMI). The aim of this study was to compare the effectiveness and safety of sirolimus-eluting stents (SESs) with paclitaxel-eluting stents (PESs) in primary percutaneous coronary intervention. We retrospectively examined 127 STEMI patients who underwent primary percutaneous coronary intervention. PES group consisted of 79 patients and SES group consisted of 48 patients. Patients were analyzed for major adverse cardiac events (MACE) and stent thrombosis (ST). The mean follow-up period was 2 years. The mean age was 53 ± 11 years in the SES group and 59 ± 11 years in the PES group (p = 0.03). Baseline and procedural characteristics were similar in the two groups except stent lengths, which was longer in the SES group. Two-year MACE rates were 8.3% in the SES group and 16.4% in the PES group (p = 0.28). Rates for ST for SES and PES groups were as follows: early ST was 2.08 versus 2.53%; late ST was 2.08 versus 2.53%; and very late ST was 2.08 versus 2.53% (p > 0.05). There were no statistically significant differences in MACE and ST rates between the SES and PES groups in the 2-year follow-up period. High ST rates detected in our study need to be clarified with future prospective and randomized clinical trials.
Keywords: sirolimus, paclitaxel, percutaneous coronary intervention, myocardial infarction
The benefit of primary pecutaneous coronary intervention (PCI) using stents has been proved with numerous studies in ST segment elevation myocardial infarction (STEMI).1,2 It has been shown that drug-eluting stents (DESs) significantly reduce restenosis and repeated interventions compared with bare metal stents in de novo noncomplex coronary lesions.3,4,5 However, thrombotic state of STEMI raises some concerns over the incidence of stent thrombosis (ST) using DESs. Two recently published trials showed the safety and efficacy of paclitaxel-eluting stents (PESs) and sirolimus-eluting stents (SESs) in treatment of STEMI.6,7 But clinical trials comparing different DESs in the treatment of STEMI are very limited. Here we report single-center real-world experience with 2 years of clinical outcomes in STEMI patients, comparing the results of PESs and SESs.
Patient Selection
This study was retrospective, single-center analysis of 127 consecutive STEMI patients who were treated with PESs (79 patients) and SESs (48 patients) between February 2004 and July 2007. All patients with STEMI including cardiogenic shock were included into the study. Use of SESs, PESs, and glycoprotein IIb/IIIa inhibitors was left to the operator's discretion. Stenting of the target lesion was performed using standard interventional techniques, without routinely dilating stent after implantation. All patients received standard pharmacological therapy including unfractionated heparin, aspirin, and clopidogrel. Aspirin (80 to 300 mg/d) was maintained indefinitely and clopidogrel (75 mg/d) was prescribed for a minimum duration of 6 months.
Definitions and End Points
Patients were analyzed for ST and major adverse cardiac events (MACE) by using office follow-up charts and telephone interviews. Follow-up period began with in-hospital period and extended up to 2 years. MACE was defined as death, repeat myocardial infarction (MI) (STEMI and non-ST elevation myocardial infarction [NSTEMI]), target lesion revascularization, and target vessel revascularization. MI was defined as presence of at least two of the followings: ischemic symptoms, new electrocardiographic changes compatible with ischemia, and raised creatinine kinase-MB levels >3 times the upper limit of normal. Target lesion revascularization was defined as a repeat intervention (surgical or percutaneous) to treat luminal stenosis within the stent or proximal or distal 5-mm edge segments. Target vessel revascularization was defined as repeat surgical or percutaneous intervention driven by any lesion located in previously treated vessel. ST was defined as definite and probable according to the Academic Research Consortium.8
Statistical Analysis
Continuous variables were presented as mean ± 1 standard deviation. Yates chi-square or Fisher exact test was used to compare the groups on qualitative variables (comparison of two proportions). Unpaired Student t test or Mann-Whitney U-test was performed for group comparison with continuous, nonparametric, or parametric variables. All statistical analyses were performed using Instat (Instat V3.05 2000, GraphPad Software, San Diego, CA). For all analyses, a two-tailed p < 0.05 was considered statistically significant.
The mean age was 53 ± 11 years in the SES group and 59 ± 11 years in the PES group (p = 0.03). There were no difference between the two groups in cardiovascular risk profile and cardiac history (Table 1). Stent length was 26.2 ± 6.4 mm in the SES group and 21.7 ± 7.4 mm in the PES group and the difference was statistically significant (p = 0.0004). Other procedural characteristics including thromboysis in myocardial infarction flow grades before and after PCI were not different in SES and PES groups (Table 2). In-hospital death rates were 2.08% in the SES group and 2.53% in the PES group (p = 1.00). Two-year MACE rates were 8.3% in the SES group and 16.4% in the PES group (p = 0.28) (Table 3). The individual components of MACE in patients with SES versus PES group were as follows: death, 6.25 versus 6.32% (p = 1.00); target lesion revascularization 2.08 versus 7.59% (p = 0.25); target vessel revascularization 0 versus 1.26% (p = 1.00); MI 6.25 versus 7.59% (p = 1.00); and ST 6.25 versus 7.59% (p = 1.00). Rates for early, late, and very late ST for SES and PES groups were as follows: early ST was 2.08 versus 2.53%; late ST was 2.08 versus 2.53%; and very late ST was 2.08 versus 2.53% (p > 0.05 for all comparisons).
Table 1
Table 1
Baseline Characteristics of the Study Groups
Table 2
Table 2
Procedural Characteristics of the Study Groups
Table 3
Table 3
Clinical Outcomes at 2 Years in the Study Groups
In this study we compared the efficacy of SES and PES in real-world patients with acute STEMI undergoing primary PCI. There were no significant differences between the two stents regarding the incidence of 2-year MACE (8.3% in SES vs. 16.4% in PES; p = 0.28) and ST rates (6.25% in SES, 7.59% in PES; p = 1.0). Recent prospective trials which compared bare-metal stents with DESs in primary PCI showed superiority of DESs in terms of target vessel revascularization with similar rates of death, reinfarction, and ST.7,9,10 TYPHOON and PASSION trials were large randomized clinical trials which investigate the safety and effectiveness of DESs in primary PCI.7,8 The SES arm of TYPHOON and PES arm of PASSION study showed that 1-year MACE rates were 7.3 and 8.8% respectively.7,8 There were also several published studies that compared SES with PES in elective patients. In SIRTAX trial 1012 stable and unstable patients are treated with SES and PES.11 At the end of the study, investigators found fewer MACE after SES implantation, primarily by decreasing rates of clinical and angiographic restenosis.
Galløe et al compared SES with PES in broad range of patients including STEMI, NSTEMI, unstable angina pectoris, and stable angina.12 In this randomized trial, there were no significant differences in clinical outcomes between patients receiving SES and PES. However, data from the comparison of the different DES type in primary PCI are very limited. The PROSIT trial randomized 308 patients with STEMI to SES and PES.13 There were no differences regarding primary end points (death, reinfarction, ST, and target lesion revascularization) between two stents in 12-month follow-up (5.8% in SES vs. 11.7% in PES; p > 0.05). The results of that study were also consistent with our findings. T-SEARCH and RESEARCH registries compared SES and PES in different clinical situations including STEMI.14 In the relatively small subgroup analysis the incidence of MACE was similar between SES and PES groups. ZEST-AMI trial compared the effectiveness of zotarilimus-eluting stent, SES, and PES in primary PCI patients.15 This multicenter, prospective, and randomized trial included 328 STEMI patients. At 12 months, cumulative incidence rates of MACE between zotarilimus-eluting stent, SES, and PES groups were not different from each other.15
The rate of ST in our study (definite and probable according to Academic Research Consortium criteria) was 6.25% in the SES group and 7.59% in the PES group at 2 years. This rate was much higher than the previously reported rates of ST in large meta-analyses, which showed rates of cumulative ST to be 1.5% for SES and 1.8% for PES at 4 years.16 It was also higher than 1.3% reported ST rate for the PES group in PROSIT trial.13 In SES arm of TYPHOON trial ST rate at 1 year was 3.4% and in PES group in HORIZON-AMI trial ST rate at 1 year was 3.2%.7,17 The difference between ST rates may be due to several reasons. First, the STEMI itself is an independent predictor of ST. In the report by Romano et al, ST rate at 2 years was 3.2% in real-world STEMI patients treated with DES which was higher than previous trial of DES that included only elective cases18 (ST rate ranged from 0 to 1.1%). Second, the high rate of ST in our study may be related with patient characteristics, as 10% of our patients were in shock; in-hospital thrombotic rates and mortality was higher than previous randomized trials. Similarly, recent report of real-world patients showed 5.1% ST (definite and probable) at 6 months which was very high.19 Third, the definition of ST may differ between trials. Some studies defined ST as angiographic documentation of thrombus in stented vessel. But this definition did not include Academic Research Consortium defined probable ST. Angiographic documentation of thrombus in the present study was 2.08% in the SES group and 5.06% in the PES group. Fourth, almost all currently available trials have provided relatively short-term data (<12 months) which did not reflect the incidence of very late ST (>1 year). In our trial very late ST rates were 2.08% in the SES group and 2.53% in the PES group, so high ST rates may be related with the 2-year follow-up period of our study. But at the end it is hard to draw clear conclusion regarding ST from such a small number of patients and bigger trials are needed to clarify this issue.
The most important limitations of our study were retrospective design, small sample size, and the lack of multivariable statistical analysis.
Conclusion
The present trial showed that in patients with STEMI who were undergoing primary PCI, SES and PES had similar outcomes in a 2-year follow-up period. The reason for high ST rates in our study need to be investigated with further prospective and randomized clinical trials.
1. Grines C L, Cox D A, Stone G W. et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341(26):1949–1956. [PubMed]
2. Stone G W, Grines C L, Cox D A. et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346(13):957–966. [PubMed]
3. Morice M C, Serruys P W, Sousa J E. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–1780. [PubMed]
4. Moses J W, Leon M B, Popma J J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–1323. [PubMed]
5. Stone G W, Ellis S G, Cox D A. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221–231. [PubMed]
6. Laarman G J, Suttorp M J, Dirksen M T. et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355(11):1105–1113. [PubMed]
7. Spaulding C, Henry P, Teiger E. et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355(11):1093–1104. [PubMed]
8. Spaulding C, Daemen J, Boersma E, Cutlip D E, Serruys P W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989–997. [PubMed]
9. Kastrati A, Dibra A, Spaulding C. et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706–2713. [PubMed]
10. De Luca G, Valgimigli M, Spaulding C. et al. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis. 2009;28(2):200–210. [PubMed]
11. Windecker S, Remondino A, Eberli F R. et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353(7):653–662. [PubMed]
12. Galløe A M, Thuesen L, Kelbaek H. et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008;299(4):409–416. [PubMed]
13. Lee J H, Kim H S, Lee S W. et al. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv. 2008;72(1):25–32. [PubMed]
14. Daemen J, Tanimoto S, García-García H M. et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries) Am J Cardiol. 2007;99(8):1027–1032. [PubMed]
15. Lee C W, Park D W, Lee S H. et al. Comparison of the efficacy and safety of zotarilimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST elevation myocardial infarction. Am J Cardiol. 2009;104:1370–1376. [PubMed]
16. Mauri L, Hsieh W H, Massaro J M, Ho K KL, D'Agostino R, Cutlip D E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020–1029. [PubMed]
17. Stone G W, Lansky A J, Pocock S J. et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360(19):1946–1959. [PubMed]
18. Romano M, Buffoli F, Tomasi L, Corrado L, Ferrari M R, Zanini R. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty. Catheter Cardiovasc Interv. 2008;71(6):759–763. [PubMed]
19. Buonamici P, Marcucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312–2317. [PubMed]
Articles from The International Journal of Angiology : Official Publication of the International College of Angiology, Inc are provided here courtesy of
Thieme Medical Publishers